Related Experiment Video

Updated: Sep 27, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

[Clinical significance and the treatment of myocardial bridge]

C C Li1, X Q Pu, S Q Ouyang

  • 1Department of Cardiology, Xiangya Hospital, Central South University, Changsha 410008, China.

Hunan Yi Ke Da Xue Xue Bao = Hunan Yike Daxue Xuebao = Bulletin of Hunan Medical University
|January 23, 2003
PubMed

Insights

Myocardial bridges, a condition where heart muscle tissue covers an artery, were found in 1.6% of patients undergoing coronary angiography. These bridges can cause myocardial ischemia and angina, but beta-blocker treatment offers effective relief and a good prognosis.

Area of Science:

  • Cardiology
  • Vascular Biology
  • Diagnostic Imaging

Background:

  • Myocardial bridges are congenital anomalies where a segment of coronary artery tunneled within the myocardium.
  • Their clinical significance and prevalence in patients undergoing coronary angiography require further exploration.

Purpose of the Study:

  • To determine the incidence of myocardial bridges in patients undergoing coronary angiography.
  • To evaluate the clinical significance and impact of myocardial bridges on myocardial ischemia and patient outcomes.

Main Methods:

  • Retrospective analysis of 861 patients who underwent coronary angiography.
  • Identification and characterization of myocardial bridges, including location and degree of stenosis.
  • Assessment of clinical symptoms, electrocardiographic changes, and diagnostic tests (exercise stress test, radionuclide myocardial perfusion imaging).

Main Results:

  • A prevalence rate of 1.6% for myocardial bridges was detected in 14 out of 861 patients.
  • All identified myocardial bridges were located in the left anterior descending branches, with varying degrees of stenosis (Grade I-III).
  • Patients with myocardial bridges presented with symptoms of myocardial ischemia and positive diagnostic tests; however, beta-blocker therapy led to symptom relief and favorable long-term outcomes without major adverse cardiac events.

Conclusions:

  • Myocardial bridges are an important consideration in patients presenting with symptoms of myocardial ischemia.
  • Beta-blocking agents are an effective treatment strategy for managing symptoms and improving prognosis in patients with myocardial bridges.
  • The long-term prognosis for patients with myocardial bridges appears favorable compared to those with stable coronary artery disease.

More Related Videos

Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft05:25

Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft

Published on: September 15, 2023

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...